SLNO

Soleno Therapeutics Stock Analysis

AI Rating

Low
  • Quality5/10
  • Growth↓ 0/10
  • Momentum↓ 2/10
Soleno Therapeutics sales and earnings growth
SLNO Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 31.48%
  • FCF Y/Y↑ 49.80%
Soleno Therapeutics gross and profit margin trends
SLNO Profitability
Neutral
  • Gross margin ↑ 98.10%
  • EPS margin↓ -79.50%
  • ROIC↓ -25.00%
Soleno Therapeutics net debt vs free cash flow
SLNO Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -17.0

Soleno Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗